CLIFFORD AMOS: Open Payments
NPI 1023098514 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,315 in 284 payments from 21 companies in 2025. Trend: 2023 $4,088 · 2024 $4,711 · 2025 $5,315
Food & beverage: $5,216Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 50 | $1,071 |
| ABBVIE INC. | 36 | $637 |
| UCB, Inc. | 29 | $547 |
| Amgen Inc. | 18 | $401 |
| Regeneron Healthcare Solutions, Inc. | 23 | $390 |
| Novartis Pharmaceuticals Corporation | 23 | $370 |
| GENZYME CORPORATION | 13 | $362 |
| Arcutis Biotherapeutics, Inc. | 16 | $302 |
| Lilly USA, LLC | 9 | $258 |
| Galderma Laboratories, L.P. | 14 | $203 |
Products named: TREMFYA, DUPIXENT, SKYRIZI, Bimzelx, OTEZLA, Zoryve, COSENTYX, NEMLUVIO.
Industry payments across MD — which companies pay providers there.
